证券代码：300199 证券简称：翰宇药业 公告编号：2025-074 深圳翰宇药业股份有限公司 关于召开2026年第一次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 深圳翰宇药业股份有限公司（以下简称"公司"或"翰宇药业"）于2025 年12月30日召开第六届董事会第十一次会议，审议通过了《关于提请召开2026 年第一次临时股东会的议案》，现就2026年第一次临时股东会相关事项通知如下： 一、会议基本情况 1、股东会届次：2026年第一次临时股东会 2、会议召集人：公司董事会 3、公司第六届董事会第十一次会议同意召开本次股东会，本次会议召开符 合有关法律、行政法规、规范性文件和《公司章程》的规定。 4、会议召开方式：本次会议采取现场投票和网络投票相结合的方式。公司 将通过深圳证券交易所交易系统和互联网投票系统（http://wltp.cninfo.com.cn） 向全体股东提供网络形式的投票平台，公司股东可以在网络投票时间内通过上述 系统行使表决权。 5、会议召开时间： （1）现场会议召开时间：2026年1月16日（周五）下午15:30 ...

本次会议的召集、召开符合《中华人民共和国公司法》（以下简称"《公司 法》"）和《公司章程》的有关规定，会议决议合法、有效。 证券代码：300199 证券简称：翰宇药业 公告编号：2025-071 深圳翰宇药业股份有限公司 第六届董事会第十一次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 深圳翰宇药业股份有限公司（以下简称"公司"）于 2025 年 12 月 29 日以 电子邮件并电话通知方式向公司全体董事发出了关于召开第六届董事会第十一 次会议的通知。 本次会议于 2025 年 12 月 30 日下午 15:30 在公司龙华总部 2006 董事会会议 室以现场结合通讯方式召开。会议应出席董事 9 人，实际出席会议董事 9 人，其 中独立董事胡文言先生以通讯表决方式出席会议。本次会议由董事长、总裁曾少 贵先生召集和主持，公司高级管理人员列席了本次会议。 二、董事会会议审议情况 （一）审议通过《关于向银行申请授信额度并提供担保的议案》； 经审议，董事会同意公司根据经营发展需求向交通银行股份有限公司深圳分 行、浙商银行股份有限 ...

Group 1 - The core viewpoint of the news highlights the trading performance and financial metrics of Hanyu Pharmaceutical, indicating a decline in stock price and significant changes in financing activities [1][2] - On December 29, Hanyu Pharmaceutical's stock fell by 0.75%, with a trading volume of 368 million yuan, and a net financing outflow of 28.43 million yuan [1] - As of December 29, the total margin balance for Hanyu Pharmaceutical was 1.193 billion yuan, with the financing balance accounting for 7.26% of the circulating market value, indicating a high level compared to the past year [1] Group 2 - As of September 30, the number of shareholders for Hanyu Pharmaceutical reached 110,100, an increase of 74.86% from the previous period, while the average circulating shares per person decreased by 42.81% [2] - For the period from January to September 2025, Hanyu Pharmaceutical reported a revenue of 683 million yuan, representing a year-on-year growth of 82.06%, and a net profit attributable to shareholders of 71.35 million yuan, up 305.00% year-on-year [2] - Since its A-share listing, Hanyu Pharmaceutical has distributed a total of 417 million yuan in dividends, with no dividends paid in the last three years [2]

Core Viewpoint - Hanyu Pharmaceutical (300199) has completed all treatment visits for participants in the clinical trials for the weight loss indication of semaglutide, with follow-up work expected to be completed by the end of December 2023. The clinical report for both indications is anticipated to be finished by the end of March 2026 [1] Group 1 - The company has confirmed that the follow-up work for the weight loss indication will be completed by the end of December 2023 [1] - The treatment visits for the diabetes indication participants will also be completed by the end of December 2023, with follow-up work concluding in January 2026 [1] - Clinical reports for both indications are expected to be finalized by the end of March 2026, and the company will disclose relevant progress in accordance with actual circumstances [1]

证券代码：300199 证券简称：翰宇药业 公告编号：2025-070 深圳翰宇药业股份有限公司 近日，公司接到控股股东、实际控制人曾少贵先生的通知，曾少贵先生办理 了部分股票质押暨股票解除质押业务。具体事项如下： 注：本表部分数据计算时需要四舍五入，故导致各分项之和与合计数尾数存在差异。 二、备查文件 关于控股股东、实际控制人办理部分股票质押暨股票解除质 押业务的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、股东股份质押基本情况 1、本次股份质押基本情况 | 股东名称 | 是否为控股 股东或第一 大股东及其 | 本次质押 数量 | 占其所 持股份 | 占公司 总股本 | 是否为 限售股 | 是否为补 充质押 | 质押起始 日 | 质押到期日 | 质权人 | 质押 用途 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 比例 | 比例 | | | | | | | | | 一致行动人 | | | | | | | | | | | 曾少贵 | 是 | ...

Market Overview - The Shanghai Composite Index rose by 0.53% on December 24, with 26 out of the 28 sectors experiencing gains, led by the defense and electronics sectors, which increased by 2.88% and 2.12% respectively [1] - The pharmaceutical and biological sector saw a modest increase of 0.24% [1] - The agriculture, forestry, animal husbandry, and fishery sectors, along with coal, were the worst performers, declining by 0.85% and 0.70% respectively [1] Capital Flow Analysis - The net inflow of capital in the two markets reached 10.37 billion yuan, with 17 sectors experiencing net inflows [1] - The electronics sector had the highest net inflow, totaling 8.68 billion yuan, coinciding with its 2.12% increase [1] - The power equipment sector also performed well, with a 1.03% increase and a net inflow of 3.76 billion yuan [1] - Conversely, 14 sectors experienced net outflows, with the non-ferrous metals sector leading with a net outflow of 1.635 billion yuan, followed by the basic chemicals sector with 1.212 billion yuan [1] Pharmaceutical and Biological Sector - The pharmaceutical and biological sector increased by 0.24%, but faced a net outflow of 1.141 billion yuan [2] - Out of 479 stocks in this sector, 320 rose while 134 fell, with one stock hitting the daily limit down [2] - The top three stocks with significant net inflows included C Jianxin with 690 million yuan, followed by Hanyu Pharmaceutical and Innovation Medical with 134 million yuan and 68.69 million yuan respectively [2] - The sector's outflow leaders included Hainan Haiyao with a net outflow of 280 million yuan, followed by Heng Rui Pharmaceutical and Luyan Pharmaceutical with 180 million yuan and 136.53 million yuan respectively [4]

Group 1 - The core point of the article is that Hanyu Pharmaceutical has officially reached a strategic investment cooperation with Shenzhen Carbon Cloud Peptide Pharmaceutical Technology Co., Ltd. [1] - According to the agreement, Hanyu Pharmaceutical will invest 10 million yuan in cash to subscribe for the newly registered capital of Carbon Cloud Peptide [1] - After the capital increase is completed, Hanyu Pharmaceutical will hold a 0.6623% equity stake in Carbon Cloud Peptide [1]

Core Viewpoint - Hanyu Pharmaceutical has entered into a strategic investment cooperation with Shenzhen Carbon Cloud Smart Peptide Pharmaceutical Technology Co., Ltd, marking a shift from prior R&D collaboration to deeper capital binding and industrial synergy [1] Group 1 - Hanyu Pharmaceutical will invest 10 million yuan in cash to subscribe to the newly registered capital of Carbon Cloud Smart Peptide [1] - After the capital increase, Hanyu Pharmaceutical will hold a 0.6623% equity stake in Carbon Cloud Smart Peptide [1] - This partnership signifies a transition to a more integrated collaboration between the two companies [1]

证券代码：300199 证券简称：翰宇药业 公告编号：2025-069 深圳翰宇药业股份有限公司 近日，公司接到控股股东、实际控制人曾少贵先生的通知，曾少贵先生办理 了部分股票质押暨股票解除质押业务。具体事项如下： | 1、本次股份质押基本情况 | | --- | | 股东名称 | 是否为控股 股东或第一 | 本次质押 | 占其所 持股份 | 占公司 总股本 | 是否为 | 是否为补 | 质押起始 质押到期日 | 质权人 | 质押 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 大股东及其 | 数量 | 比例 | 比例 | 限售股 | 充质押 | 日 | | 用途 | | | 一致行动人 | | | | | | | | | | 曾少贵 | 是 | 13,000,000 | 13.19 | 1.47 | - | 否 | 2025/12/16至办理解除质 | 深圳市高新投保 | 融资 | | | | | | | | | 押登记之日 | 证担保有限公司 | 担保 | | 曾少贵 | 是 | 6,000,000 | 6.09 | ...

Group 1 - The company has expanded the market for its liraglutide injection beyond the United States, actively exploring over 30 countries and regions including Europe, the Middle East, and Southeast Asia [2] - The frequency of shipments is not fixed but is dynamically arranged based on rolling sales forecasts and production plans developed in collaboration with global customers [2]